Skip to main content
. 2022 Feb 5;10(3):786–798. doi: 10.1016/j.gendis.2021.12.015

Table 2.

PD susceptibility loci via GWAS or Meta-GWAS studies.

Timeline Number of risk loci Number of SNP (rs) Number of cases vs. control
 Population References
Discovery stage Replication stage
2009 3 3 1713 vs. 3978 3361 vs. 4573 Caucasian GWAS58
2009 4 23 1078 vs. 2628 612 vs. 14,139
321 vs 1614		 Japanese GWAS59
2011 11 11 5333 vs. 12,019 7053 vs. 9007 Caucasian Meta-GWAS60
2014 22 28 13,708 vs. 95,282 5353 vs. 5551 Caucasian Meta-GWAS61
2017 35 44 GWAS: 6476 vs. 302,042
Meta-analysis:
13,000+ vs. 95,000+		 5851 vs. 5866 Caucasian GWAS and meta-GWAS62
2017 73 90 779 vs. 13,227 5125 vs. 17,604 Asian GWAS63
2019 78 90 30,271 vs. 1,014,601 26,035 vs 403,190 Caucasian Meta-GWAS65
2020 11 11 6724 vs. 24,851 58,533 vs 1,871,337 Asian GWAS and meta-GWAS66